Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Clinical trial NCT06444880 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06444880
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-09
- Primary completion
- 2027-07-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.